Last reviewed · How we verify
Certifect (AMITRAZ)
Certifect, a marketed drug containing Amitraz, binds to the Alpha-2A adrenergic receptor to counteract tick paralysis, positioning it as a niche player in the veterinary market. Its key strength lies in the unique mechanism of action targeting tick paralysis, setting it apart from competitors with the same target such as amitriptyline and amiodarone. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | AMITRAZ |
|---|---|
| Target | Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) (PHASE1)
- Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Certifect CI brief — competitive landscape report
- Certifect updates RSS · CI watch RSS